uploads/2016/11/Chart-05-3-1.jpg

Performance of Novartis’s Innovative Medicines Segment in 3Q16

By

Updated

Innovative Medicines segment

Novartis’s (NVS) Innovative Medicines segment, formerly the Pharmaceutical segment, consists of products for therapeutic areas such as oncology, cardio-metabolic, immunology and dermatology, retina, respiratory, neuroscience, and established medicines. The overall contribution of the segment was ~67.0% at ~$8.2 billion for 3Q16.

Innovative Medicines includes two business units: Novartis Pharmaceuticals and Novartis Oncology.

Article continues below advertisement

Performance of key innovative medicines products

Novartis’s growth products, including Gilenya, Tasigna, Galvus, Mekinist + Tafinlar, Promacta/Revolade, Jakavi, Entresto, and Cosentyx, reported a 21.0% rise in revenues at constant currencies to $3.8 billion for 3Q16. That’s nearly 46.0% of total segment sales for the quarter.

Gilenya is an oral therapy for multiple sclerosis. Due to increased demand, revenues rose 15.0% at constant exchange rates to $790.0 million in 3Q16 compared to 3Q15. The drug had double-digit growth in most markets. Gilenya competes with Biogen’s (BIIB) Tecfidera and Sanofi’s (SNY) Aubagio.

Tasigna, a drug for the treatment of chronic myeloid leukemia, reported an 8.0% rise in revenues at constant exchange rates to $441.0 million in 3Q16. The rise followed double-digit growth in global markets, offset by a 1.0% fall in US markets. Tasigna competes with Pfizer’s (PFE) Bosulif.

Tafinlar + Mekinist is used in the treatment of BRAF V600+ metastatic melanoma. The combination is approved in more than 60 countries for the treatment of unresectable melanoma and in 35 countries for the treatment of metastatic melanoma. The combination reported a rise of 29.0% at constant exchange rates to $172.0 million in 3Q16.

To avoid the risk of investing in one company, you can consider ETFs such as the First Trust Value Line Dividend ETF (FVD), which holds ~0.50% of its total assets in Novartis.

Advertisement

More From Market Realist